Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA approves Santen's Alamast for prevention of itchy eyes due to allergic conjunctivitis

Sep. 27, 1999

InSite expands genetic research program for glaucoma

Sep. 22, 1999

Allergan enters marketing agreement with McNeil for ophthalmic ofloxacin

Sep. 17, 1999

Ciba Vision and QLT initiate T-IND clinical program for Visudyne therapy

Sep. 14, 1999

InSite Vision receives milestone payment for ISV-205 development

Sep. 9, 1999

Cambridge Antibody Technology reports positive initial results from CAT-152 trial

Sep. 7, 1999

NOS-2 inhibition with aminoguanidine prevents vision loss in rat model of glaucoma

Sep. 6, 1999

KeraVision receives FDA approval to complete enrollment for phase IIIb Intacs trial

Sep. 1, 1999

Alcon introduces ocular antiinflammatory agent in Germany

Aug. 27, 1999

Alcon suspends distribution of ophthalmic NSAIDs

Aug. 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...